IN THE UNITED STATES PATENT AND TRADEMARK OFFICE n Re the Application of: Group Art Unit: 1644

FFICE MAY 1 5 2001
TECH CENTER 1600/2900

VILEN et al. Serial No.: 09/513,024

Filed: February 25, 2000

Atty. File No.: 2879-64

For: "PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS ASSOCIATED WITH RECEPTOR-**DESENSITIZATION"**

CERTIFICATE OF MAILING

AMENDMENT AND RESPONSE

Examiner: Roark, J.

HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 ON

SHERIDAN ROSS P

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This Amendment and Response is filed in response to an Office Action having a mailing date of January 8, 2001. Enclosed is a request for a one month extension of time and the requisite fee to extend the time for responding from April 8, 2001, to May 8, 2001. No additional fees are believed to be due with this response, but if fees are due, please debit Deposit Account No. 19-1970.

Please amend and reconsider the above-identified patent application as follows.

IN THE CLAIMS:

Please cancel Claims 2, 3, 7, 8, 11, 15, 16, 17, 23-29, 34-49, without prejudice to or disclaimer of the subject matter therein.

Please amend Claims 1, 4-6, 9, 10, 12, 18-22, 30 and 33, as follows, without prejudice to or disclaimer of the subject matter therein. Claims 13, 14, 31 and 32 are reiterated below, without amendment, for the Examiner's convenience.

1. (Once Amended) A method to desensitize a B cell antigen receptor, said method comprising: contacting a B cell antigen receptor with an antibody, wherein said B cell antigen receptor has a transducer component consisting of an Iga-IgB dimer and an mIg extracellular ligand binding component, wherein said antibody binds to the extracellular